RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 est...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciscar, Marina, Trinidad, Eva M, Perez‐Chacon, Gema, Alsaleem, Mansour, Jimenez, Maria, Jimenez‐Santos, Maria J, Perez‐Montoyo, Hector, Sanz‐Moreno, Adrian, Vethencourt, Andrea, Toss, Michael, Petit, Anna, Soler‐Monso, Maria T, Lopez, Victor, Gomez‐Miragaya, Jorge, Gomez‐Aleza, Clara, Dobrolecki, Lacey E, Lewis, Michael T, Bruna, Alejandra, Mouron, Silvana, Quintela‐Fandino, Miguel, Al‐Shahrour, Fatima, Martinez‐Aranda, Antonio, Sierra, Angels, Green, Andrew R, Rakha, Emad, Gonzalez‐Suarez, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086586/
https://www.ncbi.nlm.nih.gov/pubmed/36880458
http://dx.doi.org/10.15252/emmm.202216715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086586/
https://www.ncbi.nlm.nih.gov/pubmed/36880458
http://dx.doi.org/10.15252/emmm.202216715

Ejemplares similares